History

Awards & Grants

Since our beginning in 1998, MicroPort® has been presented with numerous awards and government grants in support of our efforts to provide the people of the world with high quality medical devices at affordable prices. Some of our awards include:

2017
  • MicroPort® was awarded Five Star Credit Enterprise.
  • MicroPort® was awarded Corporate Social Responsibility Award of Shanghai Pudong District.
  • "New Technology and Clinical Application of Minimally Invasive Cardiac Surgery" Project Won the Second Prize of State Science and Technology Progress Award.
2016
  • "Key technology and industrialization platform for minimally invasive interventional and implantable medical devices" project won prestigious class II prize of State Science and Technology Advancement Award.
  • Hercules® Stent Graft and Delivery System of MicroPort® Endovascular Awarded 2016 Shanghai Top-Brand Product.
  • MicroPort® was listed among "2016 National Technology Innovation Model Enterprises."
  • MicroPort® was awarded Five Star Credit Enterprise.
  • MicroPort® was granted the Annual PMO (Project Management Office) Award and Project Management Award Finalist by PMI (Project Management Institute).

2015
  • WILLIS® clinical application project won prestigious class II prize of State Science and Technology Advancement award.
  • MicroPort Endovascular (Shanghai) Co., Ltd. and Shanghai MicroPort EP MedTech Co., Ltd. received "Shanghai Hi-Tech Enterprise" honors.
  • Received pilot project for Shanghai's 2015 cluster development of strategic emerging industrial zone.
2014
  • WILLIS® intracranial stent graft system received 2013 Shanghai new product patent certificate.
  • Selected by Ministry of Science and Technology as an innovation team in key areas for "2013 innovative talents promotion" plan
  • "微创®" and "MicroPort®" trademarks received "China Famous Trademark" honor.
2013
  • Hercules™ bifurcated stent graft system was selected as a national key new product project.
  • Four projects were listed in Shanghai Science and Technology Committee's science and technology support program.
  • "Industrialization of rapamycin target eluting stent" was selected as a major project for Shanghai 2013 strategic emerging industry.
  • "Major research of 3D mapping system and catheters for atrial fibrillation treatment" was selected as major project for Shanghai 2013 strategic emerging industry.
2012
  • WILLIS® clinical application project won Ministry of Education's Science and Technology Progress Award.
  • "R&D of Domestic implantable dual chamber pacemaker system" was selected for Shanghai Science and Technology Committee’s science and technology support program.
  • "Drug eluting stent" patent won 14th "China Patent Excellence Award".
  • Received "Top Ten Business Award" from Shanghai Biopharmaceutics Industry Association.
  • 2012 national enterprise technology center's innovation capacity building project was officially approved.
2011
  • "Cerebral vascular interventional medical device development and clinical research" project was selected for "12th Five year plan" of national science and technology support program.
  • APOLLO was selected as a national key new product project.
  • Received China Torch Program's key high-tech enterprise certification.
2010
  • "R&D and industrialization of chronic disease treatment devices" was listed as a Shanghai bio-pharmaceutics industrialization projects.
  • Received national enterprise technology center certification.
2009
  • Stent graft in surgical operation, rapamycin-eluting CoCr stent system, Hercules™ AAA/TAA stent graft system, and APOLLO™ intracranial stent system received innovation product certificates from three Shanghai municipal government agencies.
  • Drug eluting stent system received innovation product certificate from Ministry of Science and Technology.
2008
  • Awarded title of "Shanghai technology small giant enterprise" by two Shanghai municipal government agencies.
  • Firebird2™ was awarded Shanghai key new product certificate by Shanghai Science and Technology Committee.
2007
  • "Drug eluting stent" was awarded class II prize of State Science and Technology Advancement award.
2006
  • AAA/TAA stent graft systems won Shanghai municipal government's class II prize of Science and Technology Progress award.
2005
  • Aegis bifurcated stent graft system (artificial vascular stent) was selected as a national key new product project.

2004
  • Coronary stent system was selected as a national key new product project.

2001
  • Awarded title of "high-tech enterprise" by certifications from four Shanghai municipal government agencies.

In addition to the above awards, we have received numerous government grants from time to time in connection with our research and development projects.